Biotech Company** |
Pharma Company (Symbol/Country) |
Type/Product Area |
Amount |
Terms/Details (Month) |
I. MODIFIED AGREEMENTS | ||||
Affymetrix Inc. |
Hoechst Marion Roussel Inc. (unit of Hoechst AG; Germany) |
EasyAccess Gold GeneChip probe array supply agreement; companies originally signed feasibility agreement 4/97 |
$15M |
Non-exclusive, 3-year agreement, giving HMR right to purchase more than 0.1M GeneChip probe arrays capable of monitoring several 100M gene expression profiles for use in research; HMR also has right to purchase custom GeneChip products based on any gene sequence or database available to HMR; Affymetrix will receive annual subscription fee, custom design fees and per-chip fees; payments are expected to exceed $15M (1/99) |
Parke-Davis (unit of Warner-Lambert Co.; NYSE:WLA) |
EasyAccess Silver agreement; companies originally signed feasibility agreement 6/97 |
ND |
Parke-Davis gains preferential access to standard and custom GeneChip arrays, instrumentation and software to monitor gene expression for use in R&D; EasyAccess packages offer volume discounts; further details ND (2/99) |
|
Pfizer Inc. (NYSE:PFE) |
EasyAccess Silver agreement; upgrade of 7/97 supply agreement |
ND |
Pfizer gains preferential access to standard and custom GeneChip arrays, instrumentation and software to monitor gene expression for use in R&D; EasyAccess packages offer volume discounts; further details ND (3/99) |
|
Cangene Corp. |
Apotex Inc. |
Extension of 5-year collaboration signed 11/95, which covers development of certain recombinant biochemicals in Cangene's pipeline |
$25M |
Apotex extended agreement 3 years and committed an additional $25M; original $30M deal runs until 11/00; terms similar to original deal, but provide more flexibility in marketing and revenue-sharing arrangements (2/99) |
Catalytica Pharmaceuticals Inc. (subsidiary of Catalytica Inc.) |
Glaxo Wellcome Inc. (subsidiary of Glaxo Wellcome plc; NYSE:GLX) |
Amendment of supply agreement to provide for manufacture of certain products (3/16) |
$70M |
Amended agreement provides for manufacture of certain Glaxo Wellcome products by Catalytica in 1999 and 2000, with options to extend deal for another 2 years; Glaxo may also extend sterile products manufacturing portion of agreement for up to 4 years beyond 2000 (3/16) |
Cerep SA (France; Nouveau Marché: CEREP) |
Sanofi SA (France) |
Expansion of 12/97 collaboration, which calls for Cerep to develop private library of compounds for Sanofi, and grants Sanofi use of Cerep's HighThroughput Lead Development technology |
ND |
Sanofi to double annual funding commitment to Cerep in exchange for Cerep's screening of 2 additional targets (2/99) |
Cortech Inc. |
Ono Pharmaceutical Co. Ltd. (Japan) |
Expansion of 4/97 oral elastase inhibitor program to include Western rights |
$11.5M |
Cortech and Ono reached an agreement in principle granting Ono Western rights, in addition to previously covered Far Eastern territories; Ono will pay $2M upon signing of definitive agreement and milestones of up to $9.5M; Cortech may also receive royalties of 4% on Ono products based on Cortech patents sold outside the Far East (3/99) |
Corvas International Inc. |
Schering-Plough Corp. (NYSE:SGP) |
Schering returned rights to development and commercialization rights for injectable formulation of recombinant nematode anticoagulant protein 5 (rNAP5) granted under 6/97 agreement |
- |
Corvas reacquired rights to develop injectable rNAP5 alone or in collaboration with 3rd party; the focus of the companies' collaborative focus is now on oral anticoagulants (3/99) |
Cytel Corp. |
Nextran (unit of Baxter International Inc.; NYSE:BAX) |
License agreement that supercedes 9/96 supply agreement |
$4M |
Cytel licensed carbohydrate synthesis and manufacturing technology to Nextran for exclusive use in xenotransplantation (3/99) |
Entremed Inc. |
Bristol-Myers Squibb Co. (NYSE:BMY) |
Modification of 8/97 research agreement coverangiostatin (anti-angiogenic protein) |
ND |
Bristol-Myers returned angiostatin to EntreMed for further preclinical work, but retains an option to reassume development and marketing rights once clinical proof of principle is demonstrated (2/99) |
Genelabs Technologies Inc. |
DuPont Pharmaceuticals Co. (NYSE:DD) |
Renewal for 1 year of collaborative research and license agreement originally signed 12/96 |
ND |
DuPont renewed for an additional year collaboration to discover and develop drugs that control expression of certain disease-associated genes; Genelabs receives research funding, plus milestones up to $20M per gene target; total value could exceed $200M (1/99) |
IGEN International Inc. |
Novo Nordisk A/S (Denmark; NYSE: NVO) |
Purchase of IGEN's M-Series High-Throughput Drug Discovery System; Novo's Zymogenetics Inc. subsidiary signed a screening agreement 8/98 utilizing the Origen M-Series System |
ND |
Novo agreed to acquire an M-Series System, now in final stages of development, for ultra-sensitive testing in drug development; further details ND (1/99) |
Inctye Pharmaceuticals Inc. |
Johnson & Johnson (NYSE:JNJ) |
Expansion and extension of database subscription launched 1/96 |
ND |
J&J will receive access to Incyte's LifeSeq Gold assembled database, the LifeSeq Atlas mapping database, and the ZooSeq animal gene sequence and expression database; agreement is 2nd expansion of relationship; J&J will pay annual access fees, plus milestones and royalties on products developed using Incyte technology and databases (2/99) |
Inctye Pharmaceuticals Inc. |
Pharmacia & Upjohn (NYSE:PNU) |
Multi-year expansion of database subscription launched 5/97 |
ND |
P&U gains access to Incyte's PathoSeq microbial database of genomic information on bacterial and fungal microorganisms; P&U will pay annual access fees, plus royalties on products developed with Incyte technology and database information (1/99) |
Ligand Pharmaceuticals Inc. |
Eli Lilly and Co. (NYSE:LLY) |
Lilly returned rights to oral Targretin and two other RXR modulators to Ligand; original agreement signed 4/97 |
ND |
Lilly opted not to proceed with development of three 1st-generation compounds in the Retinoid X Receptor diabetes program; all rights to oral Targretin (in preclinical testing for diabetes and advanced clinical trials for cancer) and two other RXR modulators revert to Ligand; the companies are focusing on 2nd-generation compounds from the same program (2/99) |
Lynx Therapeutics Inc. |
BASF AG (Germany) |
Expansion of gene sequencing agreement and widening of the scope of BASF-LYNX Bioscience AG; original agreement signed in 1996 |
ND |
BASF's non-exclusive access to Lynx's Massively Parallel Signature Sequencing amended to include non-exclusive access to other Lynx bead-based technologies and to specify that BASF will pay Lynx's costs plus commercially reasonable profits for any experiments performed for BASF under the agreement; companies also expanded scope of BASF-LYNX joint venture to include additional central nervous system diseases and other fields of interest; BASF will commit additional $10M in funding to JV, of which $4.25M was paid to Lynx for acquisition of CNS program; additional $1M paid directly to Lynx by BASF (1/99) |
Millennium Pharmaceuticals Inc. |
Pfizer Inc. (NYSE:PFE) |
Extension and expansion of 12/94 agreement for additional 2 years; collaboration uses Millennium's platform to discover anti-fungal drug leads |
ND |
Pfizer elected to extend alliance 2 additional years, to 12/00, and added unspecified resources to the program (1/99) |
Eli Lilly and Co. (NYSE:LLY) |
Extension of 4/96 oncology alliance for 2 additional years, through 3/01 |
ND |
Original agreement calls for Lilly to fund research program in target discovery and validation; Lilly pays milestones, plus royalties on any products in exchange for worldwide rights to develop and commercialize products (1/99) |
|
Millennium Pharmaceuticals Inc. |
AstraZeneca plc (U.K.; NYSE:AZN) Note: Deal was originally with Astra AB (Sweden), which merged 4/99 with Zeneca plc (U.K.) |
Extension of 12/95 inflammatory respiratory disease alliance for additional 4 years |
ND |
Extension to full term is based, in part, on Millennium's successful delivery of inflammation drug targets and on development of Astra's target pipeline during alliance's 1st phase; Extension phase will focus on application of targets for drug discovery and continued quest for new targets; under terms of original agreement, Astra funds research and pays licensing fees; Millennium is also entitled to milestones and royalties on therapeutic products (1/99) |
Miravant Medical Technologies |
Pharmacia & Upjohn (NYSE:PNU) |
Amendment of 7/95 ophthalmology co-development agreement, plus P&U entered right of first negotiation for field of cardiovascular medicine |
$41.5M (equity; 7%) |
P&U purchased 1.1M shares for $19M ($16.71 per share), and extended a secured line of credit of up to $22.5M; companies amended ophtalmology agreement; P&U assumes control of the clinical and regulatory aspects of joint ophthalmology programs, including SnET2 (tin ethyl etiopurpurin) for age-related macular degeneration; agreement terminates milestone provisions for ARMD and will require Miravant to account for the costs to be borne by P&U for additional responsibilities; companies also agreed that if Miravant develops SnET2 in cardiovascular field, P&U has right to 1st negotiation to acquire marketing rights (2/99) |
Nanogen Inc. |
Aventis Research and Technologies (affiliate of Hoechst AG; Germany; NYSE:HOE) |
Executed definitive research agreement extending program from 2 to 3 years; companies first signed exclusive R&D collaboration to develop microarray platforms and related devices and applications using Nanogen's semiconductor microchip technology in combination with Aventis' Exponential Library by Association of Sublibraries technology |
ND |
Companies executed definitive collaborative R&D agreement detailing rights and responsibilities of the parties under the collaboration, and extended term of research program from 2 to 3 years, ensuring Nanogen substantial additional funding for the 3rd year (1/99) |
Neose Technologies Inc. |
McNeil Specialty Products Co. (subsidiary of Johnson & Johnson; NYSE: JNJ) |
Expansion and extension of 11/97 joint development project to commercialize manufacturing technologies for certain complex carbohydrates |
$4M (equity; 3%) |
Neose and McNeil contemplate building a factory capable of producing at least 1 commercially promising complex carbohydrate product within a year; the compound is undisclosed but is currently widely used in food and healthcare industries; McNeil will provide substantially all of the development and capital costs of the project; concurrent with the deal's expansion, Johnson & Johnson Development Corp. agreed to invest $4M at per-share price equal to average closing price of 20 days prior to closing (1/99) |
PowderJect Vaccines Inc. (subsidiary of PowderJect Pharmaceuticals plc.) |
Glaxo Wellcome plc (U.K.; NYSE: GLX) |
Expansion of 3/98 DNA vaccines collaboration |
$1.5M |
Glaxo exercised option on a DNA vaccine product, in addition to prophylactic DNA vaccine for hepatitis B covered in original agreement; Glaxo also licensed 1 of the 7 vaccines over which it already held an option; PowderJect received $1.5M; PowderJect also received $1M payment for positive clinical trial results for prophylactic hepatitis B vaccine, to which Glaxo has exclusive rights (1/99) |
Scios Inc. |
Eli Lilly and Co. (NYSE:LLY) |
Extension of 4/97 Alzheimer's disease collaboration; development of screening assays has been a major area of focus |
ND |
Agreement provides additional research funding to Scios and extends deal at least throught 4/01; commercializing partner will pay milestones and royalties (1/99) |
Sonus Pharmaceuticals Inc. |
Abbott Laboratories Inc. (NYSE: ABT) |
Amendments to 10/96 marketing and distribution agreements for EchoGen (perflenapent injectable emulsion) |
ND |
Royalty rates reduced for international sales, and U.S. and international milestone events were redefined; U.S. royalty rates and aggregate amount of milestone payments were not changed; provisions were added allowing Sonus to request that Abbott make milestone payments in advance of the achievement of certain milestones, in exchange for Sonus common stock (2/99) |
Synaptic Pharmaceutical Corp. |
Eli Lilly and Co. (NYSE:LLY) |
Lilly discontinued commercial development of LY334370 migraine compound covered under 1/91 agreement- |
|
Lilly discontinued development following review of data from ongoing confirmatory animal toxicology study; Lilly had earlier delayed start of Phase III trial; Lilly and Synaptic will continue to collaborate on development of alternative selective serotonin 1F receptor agonists with an improved safety profile (3/99) |
II. TERMINATED AGREEMENTS | ||||
Aronex Pharmaceuticals Inc. |
Genzyme Corp. |
Aronex regained worldwide rights to Atragen (liposomal formulation of all-trans retinoic acid) granted in 3/93 |
|
Aronex regained rights to Atragen, for which it filed NDA 12/98; Aronex described the action as consistent with goal of developing sales and marketing capabilities in oncology in the U.S.; the company will pursue partners to market elsewhere in the world (3/99) |
Bioject Medical Technologies Inc. |
Merck & Co. Inc. (NYSE:MRK) |
Merck withdrew from further negotiations under 7/98 agreement giving Merck limited-term, preferential rights to use Bioject's B-2000 jet injection system to study with certain Merck vaccines |
|
Companies had been actively negotiating a second agreement that would have given Merck preferred, long-term access to B-2000 jet injection system for use with vaccines (2/99) |
Cellegy Pharmaceuticals Inc. |
Glaxo Wellcome plc (U.K.; NYSE: GLX) |
Glaxo to return worldwide rights to Glylorin (monolaurin) to Cellegy; original agreement signed 11/96 |
|
Companies reached an agreement in principle for the return to Cellegy of worldwide rights to Glylorin (monolaurin), a potential treatment for ichthyosis vugaris; shift in Glaxo's R&D priorities prompted Cellegy to request return of product; Cellegy plans to seek new partner (3/99) |
Chiroscience Group plc |
Zeneca Group plc (NYSE:AZN) Note: Zeneca merged with Astra AB 4/99 to form AstraZeneca plc |
Chiroscience will take back all rights to Chirocaine granted to Zeneca under 3/98 agreement |
$32.2M |
Companies reached an agreement in principle for return of Chirocaine rights granted to Zeneca for territories except Japan; action results from European Union regulatory officials' concern that when Zeneca merges with Astra AB, the combined entity, AstraZeneca, would potentially have too large a share of the long-acting anesthetic market in Europe Zeneca will make £10M ($16.1M) payment to compensate for impact, provide transitional funding for clinical trials and regulatory submissions, marketing support for upcoming anestheasia conferences, and an estimated £10M ($16.1M) funding of line extensions; the lock-up period of the Zeneca's 3.5M shares (3.1% stake) in Chiroscience will also be extended, and Zeneca will be required to dispose of shares at the end of the period (3/99) |
Hyal Pharmaceutical Corp. |
Fujisawa Healthcare Inc. (subsidiary of Fujisawa; Japan) |
Fujisawa decided not to license Solarase for North America |
|
Fujisawa opted against licensing Solarase for North America (3/99) |
Medarex Inc. |
Novartis AG (Switzerland) |
Medarex reacquired worldwide rights to MDX-210 anti-HER2 cancer product granted 5/95 to Ciba-Geigy Ltd. (which since merged with Sandoz to form Novartis) |
|
Novartis returned rights to MDX-210, a bi-specific anticancer antibody targeting HER2; Medarex will seek other partners as the product heads into Phase III trials; Medarex and Novartis will continue in $50M HuMAB-Mouse technology deal, which has produced an initial product candidate (2/99) |
NeuroSearch A/S (Denmark; Copenhagen Stock Exchange: NEUS.CO) |
Pharmacia & Upjohn (NYSE: PNU) |
P&U terminated 7/98 agreement on NS2710 for anxiety, which covered territories not covered by NeuroSearch (Nordic and Baltic countries) or Meiji Seika (Japan and Asia) |
|
P&U terminated licensing agreement following completion of first Phase II trial for generalized anxiety disorders, which achieved statistical significance of efficacy but produced sedation at high doses and a few cases of allergic reactions; NeuroSearch will evaluate allergic reactions further and expects to continue development (3/99) |